Despite progress in decreasing rejection and improving short-term survival (1), much of it through improved immunosuppression and anti-infective agents, late kidney allograft loss remains a problem. With close to 5000 kidney transplants failing per year and returning the recipient to dialysis in the United States, kidney transplant failure is a leading cause of end-stage renal disease. Recent analyses of large databases reveal that late renal loss has not significantly changed despite improvements in reducing rejection (1–3).
No takes yet. Share an insight, caveat, or question.
Halloran et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: